ATE185148T1 - Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine - Google Patents

Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine

Info

Publication number
ATE185148T1
ATE185148T1 AT91403446T AT91403446T ATE185148T1 AT E185148 T1 ATE185148 T1 AT E185148T1 AT 91403446 T AT91403446 T AT 91403446T AT 91403446 T AT91403446 T AT 91403446T AT E185148 T1 ATE185148 T1 AT E185148T1
Authority
AT
Austria
Prior art keywords
hiv
lipopeptides
vaccine
cytotoxic lymphocyte
lymphocyte activating
Prior art date
Application number
AT91403446T
Other languages
English (en)
Inventor
Christophe Boutillon
Frederic Martinon
Christian Sergheraert
Remy Magne
Helena Gras-Masse
Elisabeth Gomard
Andre Tartar
Jean-Paul Levy
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9403372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE185148(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE185148T1 publication Critical patent/ATE185148T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91403446T 1990-12-18 1991-12-18 Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine ATE185148T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9015870A FR2670787B1 (fr) 1990-12-18 1990-12-18 Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.

Publications (1)

Publication Number Publication Date
ATE185148T1 true ATE185148T1 (de) 1999-10-15

Family

ID=9403372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91403446T ATE185148T1 (de) 1990-12-18 1991-12-18 Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine

Country Status (10)

Country Link
EP (3) EP0945461A1 (de)
JP (2) JP3821305B2 (de)
AT (1) ATE185148T1 (de)
CA (1) CA2057828C (de)
DE (1) DE69131662T2 (de)
DK (1) DK0491628T3 (de)
ES (1) ES2137160T3 (de)
FR (1) FR2670787B1 (de)
GR (1) GR3031889T3 (de)
SG (1) SG63621A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085083A1 (en) * 1991-12-18 1993-06-19 Richard L. Tolman Synthetic peptides comprising a cyclic hiv principal neutralizing determinant and a lipopeptide
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
FR2776926B1 (fr) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
FR2821556B1 (fr) * 2001-03-02 2003-04-25 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
CA2441809C (en) 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
AU2006274651B2 (en) 2005-06-28 2012-09-27 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
US8518410B2 (en) 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
JP5986382B2 (ja) 2009-03-10 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング癌ワクチン
US9562104B2 (en) 2009-03-10 2017-02-07 Baylor Research Institute Anti-CD40 antibodies
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
EP2688592A4 (de) 2011-03-25 2015-07-22 Baylor Res Inst Zusammensetzungen und verfahren zur immunisierung gegen den hepatitis-c-virus
ES2731524T3 (es) 2012-04-05 2019-11-15 Massachusetts Inst Technology Composiciones inmunoestimuladoras y métodos de uso de las mismas
EP3094652B1 (de) 2014-01-13 2021-09-29 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EP3941511A2 (de) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Verwendung von amphiphilen in der immunzelltherapie und zusammensetzungen dafür

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416407A (en) * 1981-11-02 1983-11-22 Dennison Manufacturing Company Dispensing of fasteners with a pivoted and disengageable feed mechanism
ZA831547B (en) * 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
EP0203676B1 (de) * 1985-04-19 1992-01-29 The Wistar Institute Of Anatomy And Biology Impfstoff für die Erzeugung einer gegen ein Virus schützenden immunogenen T-Zellen-Antwort
EP0306912A3 (de) * 1987-09-08 1989-07-05 Albany Medical College Zur selektiven Anregung der Antikörperbildung befähigte immunogene Produkte und ihre Verwendung in pharmazeutischen Zusammensetzungen.
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
GB2355009A (en) * 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts

Also Published As

Publication number Publication date
FR2670787B1 (fr) 1995-06-23
JP2004043501A (ja) 2004-02-12
DE69131662T2 (de) 2000-04-06
SG63621A1 (en) 1999-11-16
DK0491628T3 (da) 2000-04-10
EP1065212A2 (de) 2001-01-03
DE69131662D1 (de) 1999-11-04
GR3031889T3 (en) 2000-02-29
CA2057828A1 (en) 1992-06-19
FR2670787A1 (fr) 1992-06-26
ES2137160T3 (es) 1999-12-16
EP1065212A3 (de) 2001-01-10
JP3821305B2 (ja) 2006-09-13
EP0491628A3 (de) 1992-07-22
JPH04295498A (ja) 1992-10-20
CA2057828C (en) 2007-06-12
EP0491628A2 (de) 1992-06-24
EP0491628B1 (de) 1999-09-29
EP0945461A1 (de) 1999-09-29

Similar Documents

Publication Publication Date Title
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
DK532184A (da) Antigene aminosyresekvenser
GB2255093A (en) Hiv-1 core protein fragments
BR0010720A (pt) Peptìdeos de neisseria antigênicos
DE68925660D1 (de) Peptidfragmente von HIV
DK0412766T3 (da) Peptidfragmenter af HIV
NO983054L (no) Virale rekombinante pseudopartikler og anvendelse som vaksiner og som anti-tumormiddel
DK0426314T3 (da) HIV-relaterede peptider
DK0732339T3 (da) Peptider fra HIV-gag-proteinet, fremstilling og anvendelse deraf
PT99850A (pt) Processo para a preparacao de novos peptideos com efeito insulinico
ATE318842T1 (de) Antigenische ha-2 peptide
DE69128095D1 (de) Azelluläre impfstoffe
KR950032286A (ko) B형 간염 바이러스에 대한 인체면역 조절기능을 가진 펩타이드

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee